Nathan Touati

The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial

Sandro Pasquali, Sara Pizzamiglio, Nathan Touati et al. · European Journal of Cancer · 2019 · 193 citations

Surgical Oncology, Medicine, Metronomic Therapy +6

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

Attila Kollár, Robin L. Jones, Silvia Stacchiotti et al. · Acta Oncologica · 2016 · 184 citations · Full text

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Lorenzo D’Ambrosio, Nathan Touati, Jean‐Yves Blay et al. · Cancer · 2020 · 134 citations · Full text

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago et al. · The Lancet Oncology · 2018 · 126 citations

Breast Oncology, Oncology, Metronomic Therapy +7

Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials

Olivier Mir, Nathan Touati, Michela Lia et al. · Clinical Cancer Research · 2019 · 85 citations · Full text